-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival
Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Aquestive Therapeutics (NASDAQ:AQST) stock is taking off on Tuesday as investors react to positive clinical trial data from the pharmaceutical company.
Aquestive Therapeutics is developing a rival to EpiPen and the results from its Phase 2 clinical trial are in. This saw it comparing AQST-109 to EpiPen in terms of effectiveness and speed of reaction.
Using a 0.3mg dose, AQST-109 achieved a time to maximum concentration (Tmax) of 12 minutes. To put that in perspective, the Tmax for EpiPen at the same dose level is 22.5 minutes. Also, the Tmax for epinephrine injection is 45 minutes.
What's Next for AQST?
Daniel Barber, CEO of Aquestive Therapeutics, said the following about what the clinical trial results mean for the company.
"We are pleased to see that AQST-109 compared favorably to both the EpiPen and the epi 0.3mg IM injection across several measures. We believe AQST-109 will provide a meaningful addition to treating anaphylaxis and we look forward to sharing the full dataset with the FDA, which will be the basis for our end-of-Phase 2 meeting scheduled for the fourth quarter of 2022."
The positive clinical trial news has AQST stock seeing heavy trading this morning. This has roughly 10 million shares on the move as of this writing. That's quite the increase over its daily average trading volume of 669,000 shares.
AQST stock is up 4% as of Tuesday morning.
Investors seeking out more of the latest stock market news are in luck!
InvestorPlace has all of the hottest stock market coverage for Tuesday! Among that is what has shares of AMC Entertainment (NYSE:AMC) moving, this morning's biggest pre-market stock movers, and more. You can read up on all of that news at the following links!
More Tuesday Stock Market News
- APE, AMC Stock Rebound After Share Sale Plunge
- Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
- Coinbase Suffers New, $350M Legal Threat
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
The post Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival appeared first on InvestorPlace.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
InvestorPlace-股票市场新闻、股票建议和交易提示
Aquestive Therapeutics (NASDAQ:AQST) stock is taking off on Tuesday as investors react to positive clinical trial data from the pharmaceutical company.
成瘾治疗学纳斯达克(Sequoia Capital：AQST)股价周二上涨，投资者对这家制药公司积极的临床试验数据做出反应。
Aquestive Therapeutics is developing a rival to EpiPen and the results from its Phase 2 clinical trial are in. This saw it comparing AQST-109 to EpiPen in terms of effectiveness and speed of reaction.
Aqutive Treeutics正在开发一种可与EpiPen竞争的产品，其第二阶段临床试验的结果已公布。这让它在有效性和反应速度方面将AQST-109与EpiPen进行了比较。
Using a 0.3mg dose, AQST-109 achieved a time to maximum concentration (Tmax) of 12 minutes. To put that in perspective, the Tmax for EpiPen at the same dose level is 22.5 minutes. Also, the Tmax for epinephrine injection is 45 minutes.
在0.3 mg剂量下，AQST-109达到最大浓度的时间(Tmax)为12分钟。客观地说，在相同剂量水平下，EpiPen的Tmax为22.5分钟。此外，注射肾上腺素的Tmax为45分钟。
What's Next for AQST?
AQST的下一步是什么？
Daniel Barber, CEO of Aquestive Therapeutics, said the following about what the clinical trial results mean for the company.
艾奎特治疗公司首席执行官Daniel·巴伯在谈到临床试验结果对公司意味着什么时说。
"We are pleased to see that AQST-109 compared favorably to both the EpiPen and the epi 0.3mg IM injection across several measures. We believe AQST-109 will provide a meaningful addition to treating anaphylaxis and we look forward to sharing the full dataset with the FDA, which will be the basis for our end-of-Phase 2 meeting scheduled for the fourth quarter of 2022."
我们很高兴看到AQST-109在几个指标上都比EpiPen和EPI 0.3 mg肌注更有利。我们相信AQST-109将为治疗过敏反应提供一个有意义的补充，我们期待着与FDA分享完整的数据集，这将成为我们定于2022年第四季度举行的第二阶段结束会议的基础。
The positive clinical trial news has AQST stock seeing heavy trading this morning. This has roughly 10 million shares on the move as of this writing. That's quite the increase over its daily average trading volume of 669,000 shares.
积极的临床试验消息使AQST股票今天上午出现了大量交易。截至撰写本文时，该公司约有1,000万股在售。与其66.9万股的日均成交量相比，这是相当大的增幅。
AQST stock is up 4% as of Tuesday morning.
截至周二上午，AQST股价上涨了4%。
Investors seeking out more of the latest stock market news are in luck!
寻求更多最新股市消息的投资者走运了！
InvestorPlace has all of the hottest stock market coverage for Tuesday! Among that is what has shares of AMC Entertainment (NYSE:AMC) moving, this morning's biggest pre-market stock movers, and more. You can read up on all of that news at the following links!
投资商位置拥有周二最热门的股市报道！其中包括拥有的股份AMC娱乐公司(纽约证券交易所代码：AMC)Moving，今天上午最大的盘前股票走势，以及更多。你可以在下面的链接上阅读所有的新闻！
More Tuesday Stock Market News
更多周二股市新闻
- APE, AMC Stock Rebound After Share Sale Plunge
- Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
- Coinbase Suffers New, $350M Legal Threat
- APE，AMC股票在股票销售暴跌后反弹
- 今日最大的盘前炒股：周二10大涨跌股
- Coinbase遭遇新的3.5亿美元法律威胁
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
在出版日期，威廉·怀特没有(直接或间接)持有本文所述证券的任何头寸。本文表达的观点是作者的观点，以InvestorPlace.com为准出版指南.
The post Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival appeared first on InvestorPlace.
AQST后，EpiPen竞争对手的积极数据带来的股票收益首先出现在InvestorPlace上。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧